Nasdaq:US$34.13 (+0.27) | HKEX:HK$55.65 (+0.65) | AIM:£5.14 (+0)
2000
FOUNDED
HCM
NASDAQ &
LONDON AIM
13
HKEX
11
IN-HOUSE DISCOVERED
CLINICAL STAGE DRUG CANDIDATES
3
APPROVED & MARKETED
PRODUCTS IN CHINA
1
NDA SUBMITTED IN THE US &
MAA SUBMITTED TO THE EMA
~40
CLINICAL TRIALS
AROUND THE GLOBE
4,500
PERSONNEL ACROSS
THE GROUP

OUR SCIENCE

Our core research and development philosophy is to take a holistic approach and treat cancer and immunological diseases through multiple modalities and mechanisms. We have taken a science-focused approach to develop highly selective, potent and well-tolerated cancer therapies that are deliberately engineered to improve drug exposure and reduce off-target toxicities.

R&D Philosophy Pipeline Products

Events, Circulars And Forms


Corporate Presentation for Investors 2021-11-15
Morgan Stanley Asia Pacific Summit 2021 2021-11-17 - 2021-11-19
Jefferies 2021 London Healthcare Conference 2021-11-18 - 2021-11-19